[Skip to Navigation]
Invited Commentary
July 30, 2020

Faricimab Combination Therapy for Sustained Efficacy in Neovascular Age-Related Macular Degeneration

Author Affiliations
  • 1Vanderbilt Eye Institute, Nashville, Tennessee
  • 2Vanderbilt University Medical Center, Nashville, Tennessee
  • 3School of Medicine, Vanderbilt University, Nashville, Tennessee
JAMA Ophthalmol. 2020;138(9):972-973. doi:10.1001/jamaophthalmol.2020.2723

The advent of anti–vascular endothelial growth factor (anti-VEGF) therapy has represented a paradigm shift in the treatment of neovascular age-related macular degeneration (nAMD). However, anti-VEGF injections require frequent office visits for administration to maintain visual acuity gains, placing a considerable treatment burden on patients, caregivers, and the health care system. Achieving sustained efficacy with fewer injections has been a major focus of research into new therapeutic options for nAMD.

Add or change institution